Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Pancreatic Cancer: Current Progress and Future Challenges.

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains one of the highly lethal malignancies. The highly refractory nature of clinically advanced disease and lack of a reliable biomarker for early detection are major obstructions in improving patient outcome. The recent efforts, however, in understanding the pancreatic tumor biology have resulted in the reco...

Retroperitoneal bronchogenic cyst mimicking pancreatic cystic lesion.

Retroperitoneal bronchogenic cyst is detected extremely rarely and often masquerades as other diseases. Here, we report 2 cases of retroperitoneal bronchogenic cyst mimicking pancreatic mucinous tumor. Histologically, both cysts were composed of ciliated respiratory-like epithelium with abundant mucin content, smooth muscle bundles and mature cartilage, compatible with the diagnosis of retroper...

Biomarkers of pancreatic cancer.

Pancreatic cancer has a high mortality rate since early diagnosis is difficult and radical operation is challenging. Classical tumor markers are reliable parameters to determine disease progression during chemotherapy or recurrence after surgery, but they are not adequate to identify suspected disease or for screening. Endoscopic brushing cytology or biopsy from the stenotic duct is widely perf...

Current trends in pancreatic cystic neoplasms.

OBJECTIVE To define how patients with pancreatic cysts are being diagnosed and treated. DESIGN Retrospective case series. SETTING University-affiliated tertiary care center. PATIENTS Four hundred one patients evaluated in the Department of Surgery between January 2004 and December 2007. MAIN OUTCOME MEASURES Clinical management, histological diagnosis, and results of surveillance. RES...

Novel Biomarkers in Pancreatic Cancer